Image - Clinical Investigation (2021) Volume 11, Issue 1

Use of Cladribine for multiple sclerosis treatment: An image article

Corresponding Author:
Jeniffer Stewert
Editorial Office, Clinical Investigation, London, UK
E-mail: stewertj@hotmail.com

Abstract

Cladribine reaches the cell via proteins that hold nucleoside. Cladribine is activated within the cell by three subsequent phosphorylations, the first being deoxycytidine kinase. The enzyme 5'-nucleotidase (5'-NTase), active cladribine can be inactivated by dephosphorylation.

Figure 1: Cladribine reaches the cell via proteins that hold nucleoside. Cladribine is activated within the cell by three subsequent phosphorylations, the first being deoxycytidine kinase. The enzyme 5’-nucleotidase (5’-NTase), active cladribine can be inactivated by dephosphorylation. Lymphocytes have a strong deoxycytidine kinase content and a low 5’-NTase concentration relative to other cells and thus have higher phosphorylated molecule concentrations that are stuck within the cell contributing to preferential phosphorylated, or triggered, cladribine aggregation.

Awards Nomination 20+ Million Readerbase

Select your language of interest to view the total content in your interested language


Google Scholar citation report
Citations : 2998

Clinical Investigation received 2998 citations as per Google Scholar report


Clinical Investigation peer review process verified at publons

Indexed In

flyer